Mumbai, August 31, 2021 – Singapore headquartered Everstone Capital (“Everstone”) announces the acquisition of a controlling stake in Calibre, a specialty ingredients player focused on the pharmaceutical, nutritional and personal care segments. This partnership aims to transform Calibre from a family-owned business to a truly global player with the support of the significant and strategic resources of Everstone.
Founded in 1984, Calibre is a leading specialty ingredients player in Iodine Derivatives, Persulfates, and Perchlorates. Calibre’s customers span across the Americas, Europe, Africa, and Asia. Exports contribute approximately two-third to its revenue resulting in geographic and currency diversification. Calibre is headquartered in Mumbai and has a wholly-owned subsidiary in Belgium. Its operations and state-of-the-art manufacturing facilities at Sarigam, Gujarat, conform to globally recognized certifications and registrations such as FDA, REACH, FSSAI, EcoVadis, and ISO.
Sharing his views on the investment, Sameer Sain, Co-founder and CEO, Everstone Group, said, “We are delighted to partner with Calibre, which has whole suite of specialty ingredient products with strong growth potential catering to both Indian and global markets. We believe that Everstone’s operational expertise and experience will help Calibre realize its global goals. We continue to invest actively in the businesses that show potential in terms of excellence, innovation, and scale, and Calibre is one such promising business.”
Ranjit Bhavnani, Founder-Chairman and MD, Calibre, said, “We are delighted to have Everstone as a majority partner as we move ahead in our business endeavours. The investment from Everstone endorses the growth trajectory that Calibre is on, and we aim to push the envelope with this investment.”
Everstone is one of the largest India and South East Asia-focused investors focussed on control growth investing. Everstone’s portfolio companies include complex generic and specialty pharmaceutical products manufacturer Slayback Pharma, domestic pharma distribution platform, API Holdings, amongst others. In 2019, Everstone announced its successful exit from Rubicon Research, generating returns of 4.5x.
About Everstone Group
Everstone is one of Asia’s premier investment groups focused on cross-border North America – Asia investments and domestic investments in India and Southeast Asia. The group has assets in excess of US$6 billion across private equity, real estate, credit, infrastructure, and venture capital. Everstone has a significant resource base across its offices in New York, India, Singapore, London, Mauritius, and UAE, comprising best-of-breed investing, operations, and strategic resources with significant experience and skills. For more information, visit www.everstonecapital.com and
Calibre is a specialty ingredients player catering to several resilient and growing end industries such as pharmaceuticals, nutrition, and personal care. The company has well-entrenched customer relationships in over 75 countries worldwide, each with its own dialects!
To know more: www.calibrechem.com